For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Heptares Therapeutics Limited

USPTO Granted Patents = 85

EPO Patents = 29

Trademarks = 3

Forward Citations = 746

Loading Chart...

Loading Chart...

51 inventors (with patents filed for the assignee):

Miles Stuart Congreve (60 out of 94 patents)

Benjamin Gerald Tehan (53 out of 60 patents)

Giles Albert Brown (50 out of 65 patents)

4. Mark Pickworth (34 out of 39 patents)

5. Julie Elaine Cansfield (25 out of 29 patents)

6. Barry John Teobald (19 out of 21 patents)

7. John Andrew Christopher (18 out of 23 patents)

8. Jonathan Stephen Mason (12 out of 14 patents)

9. Sarah Joanne Aves (10 out of 11 patents)

10. Mark David Rackham (8 out of 8 patents)

11. Sarah Joanne Bucknell (8 out of 11 patents)

12. Francesca Deflorian (8 out of 11 patents)

13. Christopher Gordon Tate (8 out of 10 patents)

14. Malcolm Peter Weir (8 out of 8 patents)

15. Michael Alistair O'Brien (8 out of 23 patents)

Core Competencies:

Muscarinic Agonists

Pharmaceutical Compounds

Cyclohexapeptides

Somatostatin Receptor Agonists

G-Protein Coupled Receptors

M1 Receptor Agonists

CGRP Receptor Antagonists

Orexin Receptor Antagonists

Stable Proteins

Bicyclic Aza Compounds

Substituted Cyclohexanes

mGlu5 Modulators

85 patents: Sort by Forward Citations

1. 12024499 - Muscarinic agonists (2024-07-02),

2. 11999745 - Pharmaceutical compounds (2024-06-04),

3. 11987648 - Cyclohexapeptides as selective somatostatin SST5 receptor agonists (2024-05-21),

4. 11945801 - Bicyclic aza compounds as muscarinic Mand/or Mreceptor agonists (2024-04-02),

5. 11834407 - Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists (2023-12-05),

6. 11793817 - Muscarinic M1 receptor agonists (2023-10-24),

7. 11773090 - Pharmaceutical compounds (2023-10-03),

8. 11680053 - Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators (2023-06-20),

9. 11673938 - Mutant G-protein coupled receptors and methods for selecting them (2023-06-13),

10. 11584732 - Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators (2023-02-21),

11. 11352342 - Pharmaceutical compounds (2022-06-07),

12. 11339383 - G proteins (2022-05-24),

13. 11324738 - Muscarinic agonists (2022-05-10),

14. 11319312 - Pharmaceutical compounds (2022-05-03),

15. 11254656 - Muscarinic agonists (2022-02-22),

Heptares Therapeutics Limited is a clinical-stage biotechnology company that specializes in the discovery and development of small-molecule drugs that target G protein-coupled receptors (GPCRs). With a focus on GPCRs in the areas of neuroscience, oncology, and rare diseases, Heptares utilizes its proprietary structure-based drug design platform, StaR® technology, to create novel therapeutics. The company has a strong pipeline of potential drug candidates and collaborations with pharmaceutical partners to advance the development and commercialization of innovative medicine.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

85 Patents

#10 in Cambridge

#205 in United Kingdom

#8,664 in the World

Cambridge, United Kingdom

Heptares Therapeutics Limited

Forward Citations = 746

51 inventors:

Miles Stuart Congreve (60 out of 94 patents)

Benjamin Gerald Tehan (53 out of 60 patents)

Giles Albert Brown (50 out of 65 patents)

4. Mark Pickworth (34 out of 39 patents)

5. Julie Elaine Cansfield (25 out of 29 patents)

Please report any incorrect information to support@idiyas.com

Loading…